A61K 2039/804
Blood cells [leukemia, lymphoma]
Official title: {Blood cells [leukemia, lymphoma]}
A61K2039/804 (Blood cells [leukemia, lymphoma]) appears on 168 US grants and 386 published applications in this corpus.
Search patents in A61K- Granted patents
- 168
- Published applications
- 386
- Assignees
- 191
- Inventors
- 813
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 1 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 2 |
| 2013 | 2 | 2 |
| 2014 | 1 | 1 |
| 2015 | 2 | 4 |
| 2016 | 1 | 3 |
| 2017 | 1 | 6 |
| 2018 | 12 | 14 |
| 2019 | 8 | 23 |
| 2020 | 13 | 37 |
| 2021 | 21 | 71 |
| 2022 | 14 | 73 |
| 2023 | 18 | 42 |
| 2024 | 18 | 56 |
| 2025 | 38 | 25 |
| 2026 | 17 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Methods and compositions for modulating CAR-T activity25 Aug 2026US 12,715,918 B2Sana Biotechnology, Inc.
- Methods of administering chimeric antigen receptor immunotherapy18 Aug 2026US 12,709,639 B2Kite Pharma, Inc.
- Selective targeting of the TREML1/MD2 interaction by small peptide or protein and its use for vaccine adjuvants23 Jun 2026US 12,661,396 B2Ascendo Biotechnology, Inc.
- GRP78 targeted adoptive cell therapy16 Jun 2026US 12,655,192 B2St. Jude Children?S Research Hospital
- Cell6 Aug 2026US 2026/0224627 A1Autolus Limited
- Modified mrna for multicell transformation6 Aug 2026US 2026/0224703 A1Tuhura Biosciences, Inc.
- Methods for treatment using adoptive cell therapy30 Jul 2026US 2026/0216327 A1Juno Therapeutics, Inc.
- Chemokine responsive activated natural killer cells with secondary homing activation for verified targets21 May 2026US 2026/0139034 A1ImmunityBio, Inc.
- Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene14 May 2026US 2026/0132376 A1Precision BioSciences, Inc.
Most cited
By later US patents
- Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene58US 9,889,160 B2Precision BioSciences, Inc. · 2018
- Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene24US 9,889,161 B2Precision BioSciences, Inc. · 2018
- Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain17US 10,525,083 B2Novartis AG · 2020
- Anti-FcRH5 antibodies and immunoconjugates and methods of use17US 8,466,260 B2Genentech, Inc. · 2013
- Anti-FcRH5 antibodies and immunoconjugates and methods of use16US 8,617,559 B2Genetech, Inc. · 2013